Table 3.
Explorative analysis of all‐cause mortality according to different drug combinations across the left ventricular ejection fraction (LVEF) spectrum
| All‐cause mortality | Overall | LVEF < 30% | LVEF 30–39% | LVEF 40–49% | LVEF ≥ 50 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. at risk (event rate/1000 py) |
HR (95% CI) P value |
No. at risk (event rate/1000 py) |
HR (95% CI) P value |
No. at risk (event rate/1000 py) |
HR (95% CI) P value |
No. at risk (event rate/1000 py) |
HR (95% CI) P value |
No. at risk (event rate/1000 py) |
HR (95% CI) P value |
||
| Poor | 7524 (205) | 1 (ref) | 1300 (257) | 1 (ref) | 1575 (204) | 1 (ref) | 1759 (187) | 1 (ref) | 2890 (198) | 1 (ref) | |
| Moderate | ACEI/ARB/ARNI + BB | 14 098 (109) |
0.69 (0.65–0.72) <0.001 |
3956 (113) |
0.62 (0.55–0.69) <0.001 |
3991 (100) |
0.64 (0.57–0.70) <0.001 |
3070 (99) |
0.67 (0.60–0.74) <0.001 |
3081 (133) |
0.76 (0.69–0.83) <0.001 |
| ACEI/ARB/ARNI + MRA | 922 (202) |
1.16 (1.03–1.31) 0.014 |
245 (201) |
0.96 (0.74–1.24) 0.766 |
196 (179) |
1.17 (0.91–1.51) 0.219 |
186 (186) |
1.26 (0.97–1.64) 0.083 |
295 (235) |
1.17 (0.94–1.45) 0.163 |
|
| BB + MRA | 1482 (281) |
1.24 (1.13–1.37) <0.001 |
269 (346) |
1.38 (1.08–1.75) 0.009 |
283 (295) |
1.10 (0.87–1.39) 0.441 |
322 (278) |
1.19 (0.95–1.48) 0.126 |
608 (256) |
1.27 (1.10–1.48) 0.002 |
|
| Good | 6486 (120) |
0.85 (0.80–0.90) <0.001 |
2539 (109) |
0.72 (0.64–0.81) <0.001 |
1704 (113) |
0.75 (0.67–0.85) <0.001 |
1132 (135) |
0.86 (0.76–0.98) 0.024 |
1111 (154) |
0.95 (0.84–1.07) 0.420 |
|
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor‐neprilysin inhibitor; BB, beta‐blocker; CI, confidence interval; HR, hazard ratio; MRA, mineralocorticoid receptor antagonist; py, person years; ref, reference.